CC16 as an Inflammatory Biomarker in Induced Sputum Reflects Chronic Obstructive Pulmonary Disease (COPD) Severity
Mengjie Chen,Kan Xu,Yuting He,Jianjun Jin,Ruolin Mao,Lei Gao,Yi Zhang,Gang Wang,Peng Gao,Min Xie,Chunfang Liu,Zhihong Chen
DOI: https://doi.org/10.2147/COPD.S400999
2023-04-27
International Journal of COPD
Abstract:Mengjie Chen, 1, &ast Kan Xu, 2, &ast Yuting He, 1, &ast Jianjun Jin, 3 Ruolin Mao, 1 Lei Gao, 1 Yi Zhang, 4 Gang Wang, 5 Peng Gao, 6 Min Xie, 7 Chunfang Liu, 8 Zhihong Chen 1 1 Department of Respiratory and Critical Care Medicine of Zhongshan Hospital, Shanghai Institute of Respiratory Disease, Fudan University, Shanghai, People's Republic of China; 2 Geriatric Department of Zhongshan Hospital, Shanghai Institute of Respiratory Disease, Fudan University, Shanghai, People's Republic of China; 3 Research Center of Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 4 Air Liquide Holding Co., Ltd, Shanghai, People's Republic of China; 5 Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu, People's Republic of China; 6 Department of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, People's Republic of China; 7 Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji Medical 10 College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 8 Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhihong Chen, Department of Respiratory and Critical Care Medicine of Zhongshan Hospital, No. 180 Fenglin Road, Shanghai, People's Republic of China, Tel +86-21-64041990-2445, Fax +86-21-64187165, Email Chunfang Liu, Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, 12&num Wlmq Road, Shanghai, People's Republic of China, Email Purpose: The progression of an abnormal inflammatory response plays a crucial role in the lung function decline of chronic obstructive pulmonary disease (COPD) patients. Compared to serum biomarkers, inflammatory biomarkers in induced sputum would be a more reliable reflection of inflammatory processes in the airways. Patients and Methods: A total of 102 COPD participants were divided into a mild-to-moderate group (FEV1%pred≥ 50%, n=57) and a severe-to-very-severe group (FEV1%pred< 50%, n=45). We measured a series of inflammatory biomarkers in induced sputum and analyzed their association with lung function and SGRQ in COPD patients. To evaluate the relationship between inflammatory biomarkers and the inflammatory phenotype, we also analyzed the correlation between biomarkers and airway eosinophilic phenotype. Results: We found increased mRNA levels of MMP9, LTB4R, and A1AR and decreased levels of CC16 mRNA in induced sputum in the severe-to-very-severe group. After adjustment for age, sex and other biomarkers, CC16 mRNA expression was positively associated with FEV1%pred (r=0.516, p=0.004) and negatively correlated with SGRQ scores (r=− 0.3538, p=0.043). As previously known, decreased CC16 was related to the migration and aggregation of eosinophils in airway. It was also found that CC16 had a moderate negative correlation with the eosinophilic inflammation in airway (r=− 0.363, p=0.045) in our COPD patients. Conclusion: Low CC16 mRNA expression levels in induced sputum were associated with low FEV1%pred and a high SGRQ score in COPD patients. Sputum CC16 as a potential biomarker for predicting COPD severity in clinical practice might attribute to the involvement of CC16 in airway eosinophilic inflammation. Keywords: COPD, induced sputum, airway inflammation, biomarkers, lung function, CC16 Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition with abnormalities of the airways and/or alveoli leading to progressive and persistent airflow limitation. 1,2 As one of the leading causes of mortality and morbidity worldwide, COPD imposes serious economic and social burdens. 3–5 Lung function is often assessed by measuring forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). 6 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is the most common standard for assessing the severity and progression of COPD according to the percentage of the predicted FEV1 value (FEV1%pred). 2 However, the heterogeneity of COPD causes great challenges in identification of the inflammatory phenotype, individualized treatment and management by lung function alone. Thus, inflammatory biomarkers may identify specific phenotypes and endotypes of COPD and enable individualized treatment for -Abstract Truncated-
respiratory system